<DOC>
	<DOCNO>NCT02924389</DOCNO>
	<brief_summary>The purpose study find well HIV medication dolutegravir get different part body : include blood plasma , special blood cell , rectal tissue . Specifically , investigator want compare fast dolutegravir lower HIV viral load three different site . In addition , investigator seek learn difference dolutegravir act male female . Results study provide information HIV medication limitation . In future , could help create good HIV medication get hard-to-reach place eventually cure HIV infection .</brief_summary>
	<brief_title>Dolutegravir Reservoirs</brief_title>
	<detailed_description>The purpose study find well HIV medication dolutegravir get different part body : include blood plasma , special blood cell , rectal tissue . Specifically , investigator want compare fast dolutegravir lower HIV viral load three different site . In addition , investigator seek learn difference dolutegravir act male female . Results study provide information HIV medication limitation . In future , could help create good HIV medication get hard-to-reach place eventually cure HIV infection . The primary aim study validate integrate population PK-VD model quantitatively describe relationship dolutegravir ( DTG ) exposure HIV viral decay blood plasma . The second aim study develop integrated population pharmacokinetic-viral dynamic ( PK-VD ) model describe relationship DTG exposure HIV viral decay peripheral blood mononuclear cell rectal tissue reservoir site . The third aim exploratory investigate sex difference DTG penetration blood plasma , peripheral blood mononuclear cell rectal tissue reservoirs reservoir well impact rectal microbiome .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Antiretroviral ( ARV ) naïve . Participants classify ARVnaïve meet follow criterion : 1 ) No ARVs ≥ 6 month never take HIV medication ≥ 30 consecutive day , 2 ) Females take ARVs pregnancy ARVs ≥ 6 month prior enrollment , 3 ) Persons whose exposure ARVs `` monotherapy '' ( mean take one class ARVs ) advent highly active antiretroviral therapy ( HAART ) . Plasma HIV1 RNA &gt; 1000 copies/mL Creatinine Clearance &gt; 50 mL/min , calculate CockcroftGault equation within 90 day screen Liver function testing , include alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase &lt; 5 time upper limit normal within 90 day screen Intact gastrointestinal tract Able willing give inform consent Willing eligible initiate ARV therapy Triumeq dolutegravir ( DTG ) tenofovir disoproxil fumarate/emtricitabine ( TDF/FTC ) Willing undergo serial blood rectal tissue sample Currently pregnant Symptomatic rectal disease time screen Currently take concurrent medication interfere DTG Bleeding diathesis Platelet count &lt; 50,000 mm3 Medical condition interferes conduct study , investigator 's opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>